drugset

drugset / Trial / NCT00110903

Treatment for Subjects With Active Rheumatoid Arthritis (RA)

NCT00110903 ↗

Phase 3 Completed Amgen

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety of etanercept liquid administered once weekly to subjects with RA.

Timeline

Start: —
Primary completion: —
Completion: —

Publications

Results Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, Zhou L, Peloso P. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007 Jan-Feb;25(1):40-6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etanercept	Protein / enzyme biologic	—	Subcutaneous

Indications